EPISODE · Jan 7, 2026 · 1H 55M
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
from Research To Practice | Oncology Videos · host Dr. Neil Love
Featuring perspectives from Dr Matthew S Davids, Dr Bita Fakhri, Prof Constantine Tam and Dr Jennifer Woyach, including the following topics: Introduction (0:00) Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids (1:42) Case: A man in his mid 70s with a plethora of comorbidities but good performance status requires treatment for CLL — Bhavana (Tina) Bhatnagar, DO (14:58) Case: A man in his early 50s, a Jehovah's Witness, under observation for IGHV-mutated CLL develops pulmonary emboli and worsening lymphadenopathy, undergoes anticoagulation and begins therapy with zanubrutinib — Jennifer Yannucci, MD Case: A man in his mid 70s with a history of atrial fibrillation on apixaban receives zanubrutinib — Zanetta S Lamar, MD (22:30) Optimal Management of Adverse Events with Bruton Tyrosine Kinase and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Prof Tam (32:50) Case: A man in his mid 90s with CLL has concurrent locally advanced Merkel cell carcinoma of the scalp — Erik Rupard, MD (50:51) Case: A woman in her early 50s under observation for IGHV-unmutated CLL develops progressive splenomegaly and receives obinutuzumab/venetoclax — Sean Warsch, MD (54:28) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Woyach (1:05:51) Case: A man in his mid 70s with high-risk (del[TP53]) CLL experiences disease progression on ibrutinib and then venetoclax/obinutuzumab — Dr Bhatnagar (1:27:23) Case: A man in his early 80s with IGHV-unmutated CLL who previously received FCR now experiences disease relapse after 5 years of acalabrutinib, and a BTK C481S resistance mutation is detected — Priya Rudolph, MD, PhD (1:29:34) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Fakhri (1:34:08) Case: A man in his early 70s with multiregimen-relapsed CLL experiences an 18-month response to pirtobrutinib — Brian P Mulherin, MD (1:50:46) CME information and select publications
Embed this episode
NOW PLAYING
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.